Repurposing Colchicine to Improve Vascular Function in Hypertension (RECTIFHY)
Primary Purpose
Essential Hypertension
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Colchicine Tablets
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Essential Hypertension focused on measuring essential hypertension, colchicine, vascular function, vascular compliance, blood pressure
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with essential hypertension
- BMI<30
- blood pressure (sys/dia) ≥120 mmhg and/or ≥80 mmhg while on hypertensive medication OR
- blood pressure (sys/dia) ≥130 mmhg and/or ≥85 mmhg without hypertensive medication
Exclusion Criteria:
- smoking
- excessive alcohol use
- chronic diseases (beside essential hypertension)
Sites / Locations
- Department of Nutrition, Exercise and Sports, UCopenhagen
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Colchicine
Placebo
Arm Description
3 weeks of treatment with colchicine
3 weeks of placebo-treatment
Outcomes
Primary Outcome Measures
Changes in vascular function with treatment measured as flowchanges with ultrasound doppler in response to infusions of isoprenaline
Infusions of isoprenalin in the brachial artery, measurement of blood flow with ultrasound doppler and intraarterial blood pressure with an intraarterial transducer for the calculation of leg vascular conductance
Changes in vascular function with training measured as flowchanges with ultrasound doppler divided by changes in blood pressure measured with intraarterial canula, in response to infusions of acetylcholine
Infusions of acetylcholine in the brachial artery, measurement of blood flow with ultrasound doppler and intraarterial blood pressure with an intraarterial transducer for the calculation of leg vascular conductance
Changes in vascular function with training measured as flowchanges with ultrasound doppler divided by changes in blood pressure measured with intraarterial canula, in response to infusions of sodium nitroprusside
Infusions of sodium nitroprusside in the brachial artery, measurement of blood flow with ultrasound doppler and intraarterial blood pressure with an intraarterial transducer for the calculation of leg vascular conductance
Secondary Outcome Measures
Blood pressure
Blood pressure measured at home with an automated blood pressure device
Vascular compliance
measured by intraarterial blood pressure and changes in arterial diameter by ultrasound doppler
Full Information
NCT ID
NCT04303689
First Posted
January 23, 2020
Last Updated
May 9, 2023
Sponsor
University of Copenhagen
Collaborators
University of Aarhus
1. Study Identification
Unique Protocol Identification Number
NCT04303689
Brief Title
Repurposing Colchicine to Improve Vascular Function in Hypertension
Acronym
RECTIFHY
Official Title
Repurposing Colchicine to Improve Vascular Function in Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
August 1, 2020 (Actual)
Primary Completion Date
December 1, 2022 (Actual)
Study Completion Date
February 28, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Copenhagen
Collaborators
University of Aarhus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this project the potential beneficial effect of the drug colchicine on vascular reactivity and blood pressure will be assessed. Colchicine is a commonly used anti-inflammatory medication approved for the treatment of gout, Familial Mediterranean Fever and pericarditis in Denmark. The current project idea is based on accumulating evidence in the literature for a beneficial role of colchicine treatment in the prevention of cardiovascular disease in parallel with novel mechanistic insight from our own research. Recently, colchicine was associated with a lower risk of cardiovascular disease, including reduced myocardial infarctions, strokes and acute coronary syndrome . However, none of these trials have investigated the effect of colchicine on arterial tone or stiffness, changes to which may underlie the reduced risk of cardiovascular disease associated with colchicine. In support of the hypothesis that colchicine will improve vascular reactivity, a study in 1985 by Lagrue et al. found that daily, low-dose colchicine improved arterial stiffness in a small cohort of hypertensive patients. More recently, colchicine was shown to improve arterial stiffness in patients with Familial Mediterranean fever supporting a cardiovascular protective role of colchicine. Finally, colchicine is also proposed to have anti-inflammatory effects in the vascular system.
Detailed Description
In this project w the potential beneficial effect of the drug colchicine on vascular reactivity and blood pressure is evaluated. Colchicine is a commonly used anti-inflammatory medication approved for the treatment of gout, Familial Mediterranean Fever and pericarditis in Denmark. The current project idea is based on accumulating evidence in the literature for a beneficial role of colchicine treatment in the prevention of cardiovascular disease in parallel with novel mechanistic insight from research of the investigators. Recently, colchicine was associated with a lower risk of cardiovascular disease, including reduced myocardial infarctions, strokes and acute coronary syndrome. However, none of these trials have investigated the effect of colchicine on arterial tone or stiffness, changes to which may underlie the reduced risk of cardiovascular disease associated with colchicine. In support of thehypothesis that colchicine will improve vascular reactivity, a study in 1985 by Lagrue et al. found that daily, low-dose colchicine improved arterial stiffness in a small cohort of hypertensive patients. More recently, colchicine was shown to improve arterial stiffness in patients with Familial Mediterranean fever supporting a cardiovascular protective role of colchicine. Finally, colchicine is also proposed to have anti-inflammatory effects in the vascular system.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Essential Hypertension
Keywords
essential hypertension, colchicine, vascular function, vascular compliance, blood pressure
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Single blinded randomized placebo-controlled intervention
Masking
Participant
Masking Description
Subjects are blinded and randomized to receive either colchicine-treatment or placebo
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Colchicine
Arm Type
Experimental
Arm Description
3 weeks of treatment with colchicine
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
3 weeks of placebo-treatment
Intervention Type
Drug
Intervention Name(s)
Colchicine Tablets
Other Intervention Name(s)
Colchicine
Intervention Description
patients with essential hypertension are randomized to receive either 3 weeks of colchicine
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
Primary Outcome Measure Information:
Title
Changes in vascular function with treatment measured as flowchanges with ultrasound doppler in response to infusions of isoprenaline
Description
Infusions of isoprenalin in the brachial artery, measurement of blood flow with ultrasound doppler and intraarterial blood pressure with an intraarterial transducer for the calculation of leg vascular conductance
Time Frame
Change in vascular conductance in response to infusions is assessed after acute treatment and before and within 72 hours after the 3 weeks of colchicine or placebo treatment
Title
Changes in vascular function with training measured as flowchanges with ultrasound doppler divided by changes in blood pressure measured with intraarterial canula, in response to infusions of acetylcholine
Description
Infusions of acetylcholine in the brachial artery, measurement of blood flow with ultrasound doppler and intraarterial blood pressure with an intraarterial transducer for the calculation of leg vascular conductance
Time Frame
Change in vascular conductance in response to infusions is assessed after acute treatment before and within 72 hours after the 3 weeks of colchicine or placebo treatment
Title
Changes in vascular function with training measured as flowchanges with ultrasound doppler divided by changes in blood pressure measured with intraarterial canula, in response to infusions of sodium nitroprusside
Description
Infusions of sodium nitroprusside in the brachial artery, measurement of blood flow with ultrasound doppler and intraarterial blood pressure with an intraarterial transducer for the calculation of leg vascular conductance
Time Frame
Change in vascular conductance in response to infusions is assessed after acute treatment and before and within 72 hours after the 3 weeks of colchicine or placebo treatment
Secondary Outcome Measure Information:
Title
Blood pressure
Description
Blood pressure measured at home with an automated blood pressure device
Time Frame
Measurements are made before and after 3 weeks of treatment with colchicine or placebo.
Title
Vascular compliance
Description
measured by intraarterial blood pressure and changes in arterial diameter by ultrasound doppler
Time Frame
Measurements are made before and after 3 weeks of treatment with colchicine or placebo.
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with essential hypertension
BMI<30
blood pressure (sys/dia) ≥120 mmhg and/or ≥80 mmhg while on hypertensive medication OR
blood pressure (sys/dia) ≥130 mmhg and/or ≥85 mmhg without hypertensive medication
Exclusion Criteria:
smoking
excessive alcohol use
chronic diseases (beside essential hypertension)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ylva Hellsten, Dr. Med. Sc.
Organizational Affiliation
University of Copenhagen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Nutrition, Exercise and Sports, UCopenhagen
City
Copenhagen
ZIP/Postal Code
2200
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Repurposing Colchicine to Improve Vascular Function in Hypertension
We'll reach out to this number within 24 hrs